您的浏览器禁用了JavaScript(一种计算机语言,用以实现您与网页的交互),请解除该禁用,或者联系我们。创美药业2022中期报告_【发现报告】
当前位置:首页/财报/招股书/报告详情/

创美药业2022中期报告

2022-09-23港股财报北***
创美药业2022中期报告

-001- 中期報告 INTERIM REPORT 2022 創美藥業股份有限公司(「公司」、「本公司」或「我們」)(股份代號:2289.HK)主營醫藥分銷業務,主要向下游分銷商和零售終端分銷西藥、中成藥、保健品等產品,並提供醫藥產品諮詢服務。公司創立於2000年,經過22年的快速發展,已成長為華南地區領先的醫藥分銷商之一。公司堅持「深耕廣東,輻射周邊」的發展戰略,在汕頭、佛山、珠海、廣州及惠州設有物流中心並擁有專業的運輸服務團隊,對非招標市場實行「半徑10公里內一日三配、50公里內一日兩配、250公里內一日一配」的高效配送機制。公司具有現代化信息系統,涵蓋整個醫藥分銷供應鏈,包括採購、銷售、倉儲、運輸及交付等。公司同時運營自建的B2B電子商務平臺:「創美e藥」,供客戶線上下單、查詢及支付等。公司於2021年全國批發企業主營業務收入前100位排序前40。 憑籍良好的信譽和優質服務,本公司近年來分別於不同的醫藥行業權威機構或協會獲得多個榮譽,包括但不限於:「醫藥商業最具發展潜力企業」、「醫藥冷鏈物流最佳物流中心(基地)」、「醫藥冷鏈物流服務推Charmacy Pharmaceutical Co., Ltd. (the “Company” or “we”) (stock code: 2289.HK) is principally engaged in the pharmaceutical distribution business. It mainly distributes western medicine, Chinese patent medicine and healthcare products to downstream distributors and retail terminals, as well as provides consultation service on pharmaceutical products. Founded in 2000, over the past 22 years of rapid development, it has become one of the leading pharmaceutical distributors in the Southern China region. The Company adheres to the development strategy of “Intensive Engagement in Guangdong Province and Extensive Coverage across Surrounding Areas”, and has built logistics centres in Shantou, Foshan, Zhuhai, Guangzhou and Huizhou, all equipped with professional transportation teams, and has a highly efficient delivery mechanism of delivering pharmaceutical products three times per day for customers within a radius of 10 kilometers, twice per day for customers within a radius of 50 kilometers and once per day for those within a radius of 250 kilometers. In addition, the Company has a modern information system that covers the entire supply chain for pharmaceutical distribution, including procurement, sales, warehousing, transportation and delivery. Apart from that, the Company operates its own B2B e-commerce platform “Charmacy e-Medicine” (創美e藥), a platform for customers to place orders online, make inquires and payment, etc. In 2021, the Company ranked top 40 among top 100 PRC wholesalers, in respect of revenue generated from the principal business. With good reputation and high-quality service, the Company has won a number of honors in different authoritative institutions or associations in the pharmaceutical industry in recent years, including but not limited to: “The Most Promising Enterprise in The Pharmaceutical Business industry”, “The Best Logistics Center For Pharmaceutical Cold Chain Logistics -002- 薦企業」、「中國物流行業金螞蟻創新獎」、「廣東省守合同重信用企業(2001-2020連續二十年)」、「抗疫積極貢獻獎」、「中國醫藥行業醫藥商業百強企業」、「醫藥供應鏈”金質獎”——十佳商業企業」、「企業信用評價AAA級信用企業」、「《藥品冷鏈物流運作規範》國家標準達標企業」等。 (Base)”, “The Medical Cold Chain Logistics Services Recommended Enterprises”, “The Golden Ant Innovation Award of Chinese Logistics Industry”, “The Title of Contract Abiding and Credit Respecting Enterprise in Guangdong Province (For 20 Consecutive Years from 2001 to 2020)”, “The Anti-Epidemic Positive Contribution Award”, “The Top 100 Pharmaceutical Enterprises in China’s Pharmaceutical Industry”, “The “Gold Award” Medical Supply Chain-- Procurement - Top Ten Commercial Enterprises”, “The AAA Credit Rating issued by the China Enterprise Confederation and the China Entrepreneurs Association”, “Obtained the National Standard of Pharmaceutical Cold Chain Logistics Operation Specification”. -003- 中期報告 INTERIM REPORT 2022 公司資料 Corporate Information 5 財務摘要 Financial Summary 7 管理層討論及分析 Management Discussion and Analysis 8 其他資料 Other Information 31 未經審核中期財務報表 The Unaudited Interim Financial Statements 38 合併資產負債表 Consolidated Balance Sheet 39 母公司資產負債表 Balance Sheet of the Parent Company 42 合併利潤表 Consolidated Income Statement 44 母公司利潤表 Income Statement of the Parent Company 47 合併現金流量表 Consolidated Statement of Cash Flow 49 母公司現金流量表 Statement of Cash Flow of the Parent Company 51 合併股東權益變動表 Consolidated Statement of Changes in Shareholder’s Equity 53 母公司股東權益變動表 Statement of Changes in Shareholder’s Equity of the Parent Company 56 未經審核中期財務報表附註 Notes To The Unaudited Interim Financial Statements 59 -005- 中期報告 INTERIM REPORT 2022 *董事 執行董事 姚創龍 (董事會主席) 鄭玉燕 張寒孜(註) 非執行董事 李偉生 嚴京斌 付征(註) 獨立非執行董事 尹智偉 周濤 關鍵(又稱關蘇哲) *監事 張玲 鄭禧玥 林志傑 *聯席公司秘書 姚潔晞 黃慧玲 *審核委員會 尹智偉(主席) 周濤 關鍵 *提名委員會 周濤(主席) 姚創龍 關鍵 *薪酬委員會 周濤(主席) 尹智偉 鄭玉燕 *風險管理委員會 姚創龍(主席) 鄭玉燕 尹智偉 *戰略發展委員會 姚創龍(主席) 鄭玉燕 周濤 * DIRECTORS Executive Directors Yao Chuanglong (Chairman of the Board) Zheng Yuyan Zhang Hanzi(Note) Non-executive Directors Li Weisheng Yan Jingbin Fu zheng(Note) Independent Non-executive Directors Wan Chi Wai Anthony Zhou Tao Guan Jian (also known as Guan Suzhe) * SUPERVISORS Zhang Ling Zheng Xiyue Lin Zhijie * JOINT COMPANY SECRETARIES Yao Jiexi Wong Wai Ling * AUDIT COMMITTEE Wan Chi Wai Anthony (Chairman) Zhou Tao Guan Jian * NOMINATION COMMITTEE Zhou Tao (Chairman)

你可能感兴趣

hot

创美药业2021中期报告

港股财报2021-09-20
hot

康哲药业2022中期报告

港股财报2022-09-06
hot

神威药业2022 中期报告

港股财报2022-09-22
公众号
小程序
pwa
桌面端
kefu
联系客服
kefu
社群